Table 1.

Patient [common variable immunodeficiency (CVID)] and control (non-CVID) group numbers and percentage in each group of studied subjects with less than 2% class-switched memory B cells (CD19⁺CD27⁺IgM–IgD⁻ B cells)

	Number of subjects studied (in brackets: percentage of studied subjects with switched memory B cells < 2% total B cells)
	CVID	Controls
No complication or immunoglobulin treatment	6 (17%)	11* (0%)
Bronchiectasis	11 (54%)	11† (27%)
Immunoglobulin treatment	23 (56%)	6‡ (0%)
Granulomatous disease	7 (86%)	9§ (0%)
Total	30 (47%)	37 (8%)

^*Healthy normal controls.

^†Bronchiectasis controls.

^‡Neurology patients on long-term immunoglobulin – immunoglobulin controls.

^§Crohn's disease patients – granulomatous controls.